Project Grant H79FG000784

Award Date 9/30/22
Completion Date 3/31/24
Dollars Obligated $2.8M
Federal Grant Program
93.493
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $876,888 to Baylor College of Medicine to conduct a multi-site randomized controlled trial evaluating the effectiveness of an automated neurocognitive training intervention to enhance the durability of rapid antidepressant effects from intravenous ketamine treatment in 600 depressed outpatients. The trial will assess the training's ability to...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under CFDA Program 93.242 Mental Health Research Grants, provides $3,412,446 to the University of Maryland, Baltimore to harness a two-state learning healthcare system and early psychosis intervention network to optimize engagement and prevent disengagement in coordinated specialty care (CSC) for youth with first episode psychosis. The project will leverage the Connection Learning Healthcare System (CLHS) to...
This federal Project Grant award from the National Institute of Mental Health (CFDA 93.242 Mental Health Research Grants) provides $878,720 to the University of Pittsburgh to conduct a multi-site randomized controlled trial. The study aims to evaluate the effectiveness of a brief automated neurocognitive training program in enhancing the real-world impact of ketamine's rapid antidepressant effects among 600 depressed outpatients receiving intravenous ketamine treatment at community-based...
This $599,740 Project Grant award from the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program will fund Northern Arizona University's (NAU) "Bridging Gaps: PA Training for Substance Use Disorder in Underserved Regions" initiative. The project aims to: 1) Improve the capacity of the current and future interdisciplinary healthcare workforce in...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to develop a Clozapine decision support tool for patients experiencing a first episode of psychosis (FEP). The $731,452 award, effective September 5, 2024, will fund a multi-center, randomized clinical trial to evaluate the use of three biomarkers - a functional brain scan and two genetic tests - to predict which FEP patients are unlikely to respond to...
This $1,873,868 Project Grant award from the National Institute on Drug Abuse (NIDA), under CFDA 93.279 - Drug Use and Addiction Research Programs, aims to develop and evaluate an intervention to improve retention in substance use disorder (SUD) treatment for pregnant patients. The key products and services to be delivered include: Developing and piloting a standardized approach to identify and address social determinants of health (SDOH) that impact SUD treatment retention for pregnant...
This Project Grant award of $289,750 from the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance program (CFDA 93.243) aims to address substance use disorder (SUD) in Eastern North Carolina. The project, titled "ECU-AMMPED: AMPLIFYING MEDICAL, MIDWIFERY, NURSE PRACTITIONER, AND DENTAL EDUCATION TO ADDRESS THE SUBSTANCE USE CRISIS IN EASTERN NC", will be implemented by...
This federal Project Grant award for $501,215 from the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program aims to provide training and education on substance use disorders (SUD) to physician assistant, clinical psychology, and clinical mental health counseling students at the University of Texas Health Science Center San Antonio (UTHSCSA) and the University of...
This K23 Project Grant, awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), provides $389,880 to develop and test a set of behavioral economics and financial incentive-based strategies to improve treatment engagement, medication adherence, and substance avoidance for patients transitioning from Coordinated Specialty Care (CSC) for first-episode psychosis to post-CSC care. The research aims to assess barriers and facilitators to...
The U.S. Department of Health and Human Services' Health Resources and Services Administration (HRSA) awarded Marillac Clinic, Inc. a $600,000 FY 2024 Project Grant under the Community Health Centers (CFDA 93.224) federal grant program. The funding will be utilized from September 1, 2024 to August 31, 2026 to dramatically expand Marillac Clinic's behavioral healthcare capacity, resulting in service to 450 new mental health patients and 200 new substance use disorder patients across seven...

CLINICAL AND EDUCATION EXPANSION OF SERVICES FOR THE INSTITUTE FOR ADVANCED DIAGNOSTICS AND THERAPEUTICS - SHEPPARD PRATT HEALTH SYSTEM, INC.'S PROPOSED CLINICAL AND EDUCATIONAL EXPANSION OF SERVICES FOR THE INSTITUTE FOR ADVANCED DIAGNOSTICS AND THERAPEUTICS PROPOSES TO SET UP A NEW EDUCATIONAL ARM, PROVIDING DURABLE, ACCESSIBLE UP TO DATE INFORMATION ON PSYCHIATRIC DIAGNOSIS AND TREATMENT, AND CREATING AN ESKETAMINE DOSING CLINIC FOR INPATIENTS AND OUTPATIENTS AT SHEPPARD PRATT. SHEPPARD PRATT'S POPULATION OF FOCUS FOR THIS PROJECT INCLUDE ADULTS WITH DIFFICULT TO TREAT MOOD DISORDERS AND CLINICIANS. SHEPPARD PRATT SEEKS TO CREATE CONTINUING EDUCATION CURRICULUM FOR MENTAL HEALTH PROVIDERS BY FIRST IDENTIFYING THE 25 MOST CRITICAL TOPICS FOR MENTAL HEALTH CARE. SHEPPARD PRATT AND COMMUNITY EXPERTS WILL DELIVER A PRESENTATION ON EACH TOPIC. THE MARKETING AND CONTINUING EDUCATION DEPARTMENTS WILL SHARE THESE FREE CME PROGRAMS ACROSS THE STATE OF MARYLAND. BY THE END OF 1-YEAR, WE WILL HAVE A LIBRARY OF 25 TAPED LECTURES TO PROVIDE CME CREDITS TO REGISTERED CLINICIANS. WE WILL SERVE 300 UNIQUE CLINICIANS WITH THIS SERVICE. WE WILL PROVIDE WEEKLY ACCESS TO PRESCRIBERS THROUGHOUT MARYLAND TO ANSWER QUESTIONS ON DIAGNOSIS AND TREATMENT WITH A PROVIDER HELP LINE. TO ACCOMPLISH THIS, WE WILL IDENTIFY EXPERTS IN THE SHEPPARD PRATT SYSTEM CAPABLE OF PROVIDING TIMELY SUPPORT TO MARYLAND PRACTITIONERS AND DEVELOP A SCHEDULE FOR WHEN EXPERTS WILL BE AVAILABLE. WE WILL ENGAGE WITH THE MARKETING DEPARTMENT AND PROVIDE COMMUNITY OUTREACH TO INFORM LOCAL PRESCRIBERS OF AVAILABILITY OF THIS NEW SHEPPARD PRATT SERVICE. ONCE IMPLEMENTED, THE HELP LINE WILL GO LIVE WITH 10 HOURS PER WEEK OF EXPERT SUPPORT. WE WILL SERVE 100 UNIQUE CLINICIANS AND 500 UNIQUE PATIENTS OVER THE DURATION OF THE 1-YEAR FUNDING PERIOD. SHEPPARD PRATT WILL PROVIDE ACCESS TO PATIENTS AND CLINICIANS TO GET IN PERSON OR VIRTUAL CONSULTATION WITH AN EXPERT CLINICIAN. WE WILL ENGAGE WITH EXPERTS FROM EACH POPULATION SHEPPARD PRATT SERVES AND COLLABORATE WITH THEM TO PROVIDE TWO HOURS OF CONSULTATION SERVICE PER MONTH. TO SUPPORT SUSTAINABILITY, NEGOTIATIONS WILL BEGIN WITH THIRD PARTY INSURERS TO AGREE TO HIGHER CONSULTATION FEES FOR COVERED PATIENTS WHO HAVE REQUIRED FREQUENT SERVICES. WE EXPECT THAT 200 UNIQUE PATIENTS WILL BENEFIT FROM THE CONSULTATION SERVICE. WE WILL PROVIDE COMMUNITY ACCESS TO AN ACADEMIC CENTER QUALITY ESKETAMINE CLINIC PROVIDING BOTH EVALUATION AND TREATMENT. A SUSTAINABILITY FRAMEWORK WILL BE IMPLEMENTED BY NEGOTIATING A MUTUALLY ACCEPTABLE REIMBURSEMENT RATE WITH THIRD PARTY INSURERS. WE WILL EVALUATE TREATMENT OUTCOMES WITH STANDARD RESEARCH SCALES AND REVIEW AND MODIFY SERVICES BASED ON OUTCOMES AND PATIENT SATISFACTION. WE WILL SERVE 35 UNIQUE INPATIENTS AND 20 UNIQUE OUTPATIENTS WITH SERVICES OFFERED AT THE ESKETAMINE DOSING CLINIC.

Posted 9/28/22, 12:00 AM